Trial Profile

Hydroxyurea for Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydroxycarbamide (Primary)
Indications Stroke; Transient ischaemic attacks
Focus Therapeutic Use
Acronyms SPRINT

Most Recent Events

02 Nov 2022 Results hypothesizing that fixed oral moderate-dose hydroxyurea (20 mg/kg/day) results in an 80% relative risk reduction of stroke or death when compared to fixed oral low-dose hydroxyurea (10 mg/kg/day) in children with sickle cell anemia published in the Blood
16 Jan 2022 Status changed from active, no longer recruiting to completed.
04 Aug 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com